1-溴-2-甲氧基-6-(3-甲氧基苯基)萘 | 1041115-67-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 1-溴-2-甲氧基-6-(3-甲氧基苯基)萘
• 英文名称: 1-bromo-2-methoxy-6-(3-methoxyphenyl)naphthalene
• CAS: 1041115-67-6
• 化学式: C₁₈H₁₅BrO₂
• 分子量: 343.22
• InChiKey: PCVPTZAJUMQSJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-溴-2-甲氧基-6-(3-甲氧基苯基)萘 在 吡啶 、 4-二甲氨基吡啶 、 四(三苯基膦)钯 、 三溴化硼 、 caesium carbonate 作用下， 以 乙二醇二甲醚 、 乙醇 、 二氯甲烷 、 水 为溶剂， -25.0~150.0 ℃ 、150.0 kPa 条件下， 反应 148.25h， 生成 N-(3-(2-hydroxy-6-(3-hydroxyphenyl)naphthalen-1-yl)phenyl)quinolin-6-sulfonamide
  参考文献：
  名称：

  Lead Optimization of 17β-HSD1 Inhibitors of the (Hydroxyphenyl)naphthol Sulfonamide Type for the Treatment of Endometriosis

  摘要：

  The reduction of estrone to estradiol, the most potent estrogen in human, is catalyzed by 17 beta-hydroxysteroid dehydrogenase type 1 (17 beta-HSD1). A promising approach for the treatment of estrogen-dependent diseases is the reduction of intracellular estradiol formation by inhibition of 17 beta-HSD1. For the species-specific optimization of the (hydroxyphenyl)naphthols, a combinatorial approach was applied and enhanced by a focused synthesis that resulted in the aromatic-substituted (hydroxyphenyl)naphthol sulfonamides. Rigidification of 12 led to the 4-indolylsulfonamide 30, which is a highly active and selective human 17 beta-HSD1 inhibitor, as well as a highly potent and selective inhibitor of 17 beta-HSD1 from Callithrix jacchus. It shows no affinity to the estrogen receptors a and 9 and good intracellular activity (T47D). Thus, compound 30 shows good properties for further ADMET studies and might be a candidate for the in vivo proof of concept in C. jacchus.

  DOI：

  10.1021/jm201735j
• 作为产物：
  描述：

  2-溴-6-甲氧基萘 在 N-溴代丁二酰亚胺(NBS) 、 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 水 、 甲苯 为溶剂， 反应 20.0h， 生成 1-溴-2-甲氧基-6-(3-甲氧基苯基)萘
  参考文献：
  名称：

  Lead Optimization of 17β-HSD1 Inhibitors of the (Hydroxyphenyl)naphthol Sulfonamide Type for the Treatment of Endometriosis

  摘要：

  The reduction of estrone to estradiol, the most potent estrogen in human, is catalyzed by 17 beta-hydroxysteroid dehydrogenase type 1 (17 beta-HSD1). A promising approach for the treatment of estrogen-dependent diseases is the reduction of intracellular estradiol formation by inhibition of 17 beta-HSD1. For the species-specific optimization of the (hydroxyphenyl)naphthols, a combinatorial approach was applied and enhanced by a focused synthesis that resulted in the aromatic-substituted (hydroxyphenyl)naphthol sulfonamides. Rigidification of 12 led to the 4-indolylsulfonamide 30, which is a highly active and selective human 17 beta-HSD1 inhibitor, as well as a highly potent and selective inhibitor of 17 beta-HSD1 from Callithrix jacchus. It shows no affinity to the estrogen receptors a and 9 and good intracellular activity (T47D). Thus, compound 30 shows good properties for further ADMET studies and might be a candidate for the in vivo proof of concept in C. jacchus.

  DOI：

  10.1021/jm201735j

文献信息

• Substituted 6-Phenyl-2-naphthols. Potent and Selective Nonsteroidal Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1): Design, Synthesis, Biological Evaluation, and Pharmacokinetics
  作者：Sandrine Marchais-Oberwinkler、Patricia Kruchten、Martin Frotscher、Erika Ziegler、Alexander Neugebauer、Umadevi Bhoga、Emmanuel Bey、Ursula Müller-Vieira、Josef Messinger、Hubert Thole、Rolf W. Hartmann

  DOI：10.1021/jm800367k

  日期：2008.8.1

  concentration is mainly regulated by 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1), which catalyzes the reduction of the weak estrogen estrone (E1) to the highly potent E2. This enzyme is thus an important target for the treatment of hormone-dependent diseases. Thirty-seven novel substituted 6-phenyl-2-naphthols were synthesized and evaluated for 17beta-HSD1 inhibition, selectivity toward 17beta-HSD2

  17β-雌二醇（E2）与雌激素依赖性疾病的发生和发展有关。它的浓度主要受17beta-羟类固醇脱氢酶1型（17beta-HSD1）调节，该酶催化将弱雌激素雌酮（E1）还原为强效E2。因此，该酶是治疗激素依赖性疾病的重要靶标。合成了37种新型取代的6-苯基-2-萘酚，并评估了其对17beta-HSD1的抑制作用，对17beta-HSD2和雌激素受体（ER）α和β的选择性以及药代动力学特性。SAR研究表明，这些化合物最有可能根据结合模式B与活性位点结合，即与类固醇A环类似的6-苯基部分。虽然苯环上的取代会降低活性，
• 17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases
  申请人：Hartmann Rolf

  公开号：US20100204234A1

  公开（公告）日：2010-08-12

  The invention relates to the use of non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment and prophylaxis of hormone-dependent, particularly estrogen-dependent, diseases. The invention further relates to suitable inhibitors and to a method for the production thereof.

  该发明涉及使用非甾体17β-羟基类固醇脱氢酶1抑制剂治疗和预防激素依赖性疾病，特别是雌激素依赖性疾病。该发明还涉及适当的抑制剂以及生产方法。
• 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-related diseases
  申请人：Hartmann Rolf

  公开号：US08546392B2

  公开（公告）日：2013-10-01

  The invention relates to the use of non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment and prophylaxis of hormone-dependent, particularly estrogen-dependent, diseases. The invention further relates to suitable inhibitors and to a method for the production thereof.

  该发明涉及使用非甾体17β-羟基类固醇脱氢酶1抑制剂治疗和预防激素依赖性疾病，特别是雌激素依赖性疾病。该发明还涉及适当的抑制剂及其生产方法。
• New Drug-Like Hydroxyphenylnaphthol Steroidomimetics As Potent and Selective 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Estrogen-Dependent Diseases
  作者：Sandrine Marchais-Oberwinkler、Marie Wetzel、Erika Ziegler、Patricia Kruchten、Ruth Werth、Claudia Henn、Rolf W. Hartmann、Martin Frotscher

  DOI：10.1021/jm1009082

  日期：2011.1.27

  Inhibition of 17 beta-hydroxysteroid dehydrogenase type 1 (17 beta-HSD1) is a novel and attractive approach to reduce the local levels of the active estrogen 17 beta-estradiol in patients with estrogen-dependent diseases like breast cancer or endometriosis. With the aim of optimizing the biological profile of 17 beta-HSD1 inhibitors from the hydroxyphenylnaphthol class, structural optimizations were performed at the 1-position of the naphthalene by introduction of different heteroaromatic rings as well as substituted phenyl groups. In the latter class of compounds, which were synthesized applying Suzuki-cross coupling, the 3-methane-sulfonamide 15 turned out to be a highly potent 17 beta-HSD1 inhibitor (IC50 = 15 nM in a cell-free assay). It was also very active in the cellular assay (T47D cells, IC50 = 71 nM) and selective toward 17 beta-HSD2 and the estrogen receptors alpha and beta. It showed a good membrane permeation and metabolic stability and was orally available in the rat.
• 17BETA-HYDROXYSTEROID-DEHYDROGENASE-TYP1-INHIBITOREN ZUR BEHANDLUNG HORMONABHÄNGIGER ERKRANKUNGEN
  申请人：Universität des Saarlandes

  公开号：EP2131826A2

  公开（公告）日：2009-12-16